Navigation Links
Study explaining parasite gene expression could help fight toxoplasmosis and malaria
Date:1/2/2014

INDIANAPOLIS -- A newly identified protein and other proteins it interacts with could become effective targets for new drugs to control the parasite that cause toxoplasmosis, researchers led by investigators at Indiana University School of Medicine have reported.

The discovery could also open new research pathways for treatments for malaria.

The researchers determined that the protein, an enzyme called GCN5b, is necessary for the Toxoplasma parasite to replicate, so interfering with its activities could control the parasite. GCN5b is part of the molecular machinery that turns genes on and off in the parasite, working with other proteins that, the researchers discovered, are more plant-like than their counterparts in humans.

"GCN5b is a very different protein than its human counterpart, and proteins it interacts with are not found in humans," said William J. Sullivan Jr., Ph.D., associate professor of pharmacology and toxicology.

"That's what makes this exciting -- rather than just having one enzyme that we could go after, there could be a whole collection of associated enzyme components that could be potentially targeted for drug therapies to control this parasite," he said.

In discovering that some of the proteins interacting with GCN5b are plant-like transcription factors -- proteins that bind to DNA -- the researchers filled in what had been a missing link explaining how the parasites control the process of turning genes on and off, known as gene expression. The plant-like transcription factors recruit the GCN5b enzyme complex to activate a wide variety of genes for expression.

When the research team disabled the GCN5b complex, parasite replication swiftly came to a halt.

Dr. Sullivan and his colleagues reported their findings in the Jan. 2, 2014, online edition of the journal PLOS Pathogens.

An estimated 60 million people in the United States are infected with the toxoplasmosis parasite, but in most cases the infection produces flu-like symptoms or no symptoms at all. However, for people with immune system problems such as those undergoing chemotherapy or people with AIDS the disease can cause serious effects including lung problems, blurred vision and seizures. Also, infants born to mothers who are infected for the first time during or shortly before pregnancy are at risk for severe complications, miscarriages or stillbirths.

One of the most common routes to human infection is via cats, in particular their feces or litter. Eating undercooked meat from infected livestock can also result in human infection.

Although there are anti-parasitic drugs available to treat acute episodes of toxoplasmosis, it's currently impossible to completely eliminate the parasite because it can switch from an active to a latent cyst form in the body. Since GCN5b is active during both acute and latent stages, the enzyme and its associating components are very promising candidates for drug targeting, Dr. Sullivan said. Because the transcription factors are plant-like proteins not found in humans, drugs targeting them would be much less likely to affect human proteins and cause adverse effects.

Researchers also use Toxoplasma as a model organism for the malaria parasite Plasmodium, meaning much of what is learned about Toxoplasma could lead to new treatments for a disease that struck an estimated 207 million people worldwide in 2012 and caused an estimated 627,000 deaths, most of them children. Dr. Sullivan noted that the malaria parasite also possesses a GCN5 enzyme, as well as the plant-like proteins.


'/>"/>

Contact: Eric Schoch
eschoch@iu.edu
317-274-8205
Indiana University
Source:Eurekalert  

Related biology news :

1. Montana State University research on algal biofuels keys larger study
2. Study finds patients give broad endorsement to stem cell research
3. Ill have what theyre having: Study finds social norms influence food choices
4. UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer
5. International team completes systematic, genomic study of cervical cancer
6. Study finds axon regeneration after Schwann cell graft to injured spinal cord
7. Slippery bark protects trees from pine beetle attack, according to CU-Boulder study
8. Study offers clues to how plants evolved to cope with cold
9. Study shows Where Alzheimers starts and how it spreads
10. Study: Some plants may not adapt quickly to future climate change
11. Wayne State cholesterol study shows algal extracts may counter effects of high fat diets
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study explaining parasite gene expression could help fight toxoplasmosis and malaria
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a ... with a flexure design that ensures high alignment accuracy by preventing unwanted shaft ... ideally suited where extreme precision is required, such as in medical equipment, laboratory ...
(Date:11/30/2016)... ALBANY, New York , November 30, 2016 /PRNewswire/ ... exceptionally consolidated as a few players hold a dominant ... Lonza Group, Charles River Laboratories International, Inc., and Merck ... global market in 2015. Transparency Market Research observes that ... they are focused on development products that are do ...
(Date:11/30/2016)... RATON, Fla. , Nov. 30, 2016 ... biotherapeutic products, is pleased to announce the addition of ... Avenue Kearney, Nebraska . The 15,200 ... business on November 29th, 2016 and brings the total ... Ileana Carlisle , BPC,s Chief Executive ...
Breaking Biology Technology: